Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Cancer
Interventions: DRUG: SHR-1316|DRUG: SHR6390|DRUG: Nab paclitaxel|DRUG: SERD|DRUG: AI
Sponsor: Fudan University
Collaborators: Peking University Cancer Hospital & Institute|First Hospital of China Medical University|Sun Yat-sen University|First Affiliated Hospital Xi'an Jiaotong University|Liaoning Tumor Hospital & Institute|Chongqing University Cancer Hospital|Northern Jiangsu People's Hospital|Fujian Medical University Union Hospital|Ningbo Medical Center Lihuili Hospital|Shanghai First Maternity and Infant Hospital|Shanghai 6th People's Hospital|Affiliated Hospital of Nantong University